Type to search

ViiV Healthcare Announces US FDA Approval of Apretude (Cabotegravir Extended-release Injectable Suspension), the First and Only Long-acting Injectable Option for HIV Prevention | Pharmtech Focus
ViiV Healthcare New Drug Application for Long-Acting Cabotegravir for Prevention of HIV | Pharmtech Focus